stockportfolio.pro
Stocks / ALKS vs PTGX
ALKS vs PTGX
Alkermes plc and Protagonist Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Alkermes plc (ALKS) | Protagonist Therapeutics, Inc. (PTGX) | |
|---|---|---|
| Market cap | $7.3B | $6.9B |
| Revenue (latest FY) | $1.48B | $46.02M |
| Net income (latest FY) | $241.66M | $-130.15M |
| Revenue growth (5y CAGR) | 7.3% | 10.0% |
| Net margin | 16.4% | -282.8% |
| Return on equity | 13.3% | -21.2% |
| P/E ratio | 49.0 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 1 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ALKS — free Open PTGX — freeFrequently asked questions
Which is bigger, ALKS or PTGX?
Alkermes plc is larger by market capitalization — $7.3B versus $6.9B.
Which grows faster, ALKS or PTGX?
Over the last five fiscal years, Protagonist Therapeutics, Inc. grew revenue faster — 10.0%/yr versus 7.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.